ftInvstr
RUBICON · Healthcare ₹1762.0 -0.62% Mkt Cap ₹29114 Cr

RUBICON

Healthcare Drug Manufacturers - General
₹1762.0
-0.62% today · 30d +14.79%
as of 2026-09-04
Price · Daily Candles
“RUBICON surges 63% in three months, yet FCF remains negative amidst DII stakeholder exodus.”
RUBICON has experienced a significant price rally, with a 3-month return of 63.88% and a 1-year return of 126.54%. This bullish sentiment appears to be driven by strong annual revenue growth of 35.31% and net profit growth of 83.64% in the last fiscal year. However, the company is current Free Cash Flow negative at -24.0 Cr, indicating its inability to generate positive cash from operations after capital expenditures.
BULL CASE
+RUBICON's stock price has soared, returning 63.88% in the last 3 months and 126.54% over the past year.
+Annual revenue witnessed a substantial 35.31% year-on-year increase for the period ending March 31, 2026.
+Net profit saw impressive growth, rising by 83.64% year-on-year for the period ending March 31, 2026.
+The 3-year revenue CAGR stands at a strong 61.16% and 5-year profit CAGR is 51.73%.
BEAR CASE
RUBICON's current Price-to-Earnings (PE) ratio of 96.78 is significantly higher than the sector median.
Despite strong revenue and profit growth, the company reports a negative Free Cash Flow of -24.0 Cr, resulting in a FCF yield of -0.1%.
ML predictions for Free Cash Flow (FCF) growth show a weak outlook, with ranks of 0.193 for 1-year recent 2-year and 0.0 for 1-year rolling 4-year and 1-year stable 7-year.
DII shareholding decreased by 0.59% quarter-on-quarter, and FII shareholding also saw a marginal dip of 0.02%.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹534 Cr
NET PROFIT
₹85 Cr
OPM
24.96%
EPS
₹5.13
PE 96.78
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-0.1% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
RUBICON trades at a PE of 96.78 with a ROCE of 26.0%, significantly higher than peers like PFIZER (PE 29.46, ROCE 25.0%) and GLAXO (PE 40.8, ROCE 60.28%).
PEERPEROCE %
RUBICON96.7826.0
GLAXO40.860.28
PFIZER29.4625.0
CORONA66.9833.8
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
69
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
Valuation STRETCHED 20
Growth STRONG 80
Profitability HIGH 85
Technicals STRONG 70
Risk LOW 90
Key Stats
TTM PE
96.78
P/B
19.62
52W HIGH
₹1899.0
OFF HIGH
-7.21%
DIV YIELD
0.1%
MKT CAP
₹29114 Cr
◉ Active Signals
MACDNeutral-9.8612
RSI(14)Neutral56.62
Street Consensus
2 analysts
₹1395.0
mean target
Low ₹1190.0Now ₹1762.0High ₹1600.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold RUBICON and at what entry.

Sign up freeSign in